Systemic therapy in stage IV pancreatic cancer

A population-based analysis using the National Cancer Data Base

Nabin Khanal, Smrity Upadhyay, Sumit Dahal, Vijaya Raj Bhatt, Peter T. Silberstein

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Pancreatic cancer accounts for approximately 7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown. Method: This is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70% of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Results: Our study demonstrated that only 49.1% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers. Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.

Original languageEnglish
Pages (from-to)198-205
Number of pages8
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number4
DOIs
StatePublished - Jul 19 2015

Fingerprint

Pancreatic Neoplasms
Databases
Population
Neoplasms
Educational Status
Therapeutics
Insurance
Hispanic Americans
African Americans
Comorbidity
Economics
Life Support Care
Puerto Rico
Medicaid
Medicare
Retrospective Studies
Drug Therapy
Health

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Systemic therapy in stage IV pancreatic cancer : A population-based analysis using the National Cancer Data Base. / Khanal, Nabin; Upadhyay, Smrity; Dahal, Sumit; Bhatt, Vijaya Raj; Silberstein, Peter T.

In: Therapeutic Advances in Medical Oncology, Vol. 7, No. 4, 19.07.2015, p. 198-205.

Research output: Contribution to journalArticle

@article{dd9c8cbf47434f1db2e294b6404ddf30,
title = "Systemic therapy in stage IV pancreatic cancer: A population-based analysis using the National Cancer Data Base",
abstract = "Background: Pancreatic cancer accounts for approximately 7{\%} of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown. Method: This is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70{\%} of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Results: Our study demonstrated that only 49.1{\%} of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers. Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.",
author = "Nabin Khanal and Smrity Upadhyay and Sumit Dahal and Bhatt, {Vijaya Raj} and Silberstein, {Peter T.}",
year = "2015",
month = "7",
day = "19",
doi = "10.1177/1758834015579313",
language = "English",
volume = "7",
pages = "198--205",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Systemic therapy in stage IV pancreatic cancer

T2 - A population-based analysis using the National Cancer Data Base

AU - Khanal, Nabin

AU - Upadhyay, Smrity

AU - Dahal, Sumit

AU - Bhatt, Vijaya Raj

AU - Silberstein, Peter T.

PY - 2015/7/19

Y1 - 2015/7/19

N2 - Background: Pancreatic cancer accounts for approximately 7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown. Method: This is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70% of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Results: Our study demonstrated that only 49.1% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers. Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.

AB - Background: Pancreatic cancer accounts for approximately 7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown. Method: This is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70% of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Results: Our study demonstrated that only 49.1% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers. Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.

UR - http://www.scopus.com/inward/record.url?scp=84931453563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931453563&partnerID=8YFLogxK

U2 - 10.1177/1758834015579313

DO - 10.1177/1758834015579313

M3 - Article

VL - 7

SP - 198

EP - 205

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 4

ER -